Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation
Open Access
- 25 November 2015
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 8, 71
Abstract
Nicotine addiction, the result of tobacco use, leads to over six million premature deaths world-wide, a number that is expected to increase by a third within the next two decades. While more than half of smokers want and attempt to quit, only a small percentage of smokers are able to quit without pharmacological interventions. Therefore, over the past decades, researchers in academia and the pharmaceutical industry have focused their attention on the development of more effective smoking cessation therapies, which is now a growing 1.9 billion dollar market. Because the role of neuronal nicotinic acetylcholine receptors (nAChR) in nicotine addiction is well established, nAChR based therapeutics remain the leading strategy for smoking cessation. However, the development of neuronal nAChR drugs that are selective for a nAChR subpopulation is challenging, and only few neuronal nAChR drugs are clinically available. Among the many neuronal nAChR subtypes that have been identified in the brain, the α4β2 subtype is the most abundant and plays a critical role in nicotine addiction. Here, we review the role of neuronal nAChRs, especially the α4β2 subtype, in the development and treatment of nicotine addiction. We also compare available smoking cessation medications and other nAChR orthosteric and allosteric ligands that have been developed with emphasis on the difficulties faced in the development of clinically useful compounds with high nAChR subtype selectivity.Keywords
This publication has 108 references indexed in Scilit:
- Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitationsBiochemical Pharmacology, 2011
- α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like propertiesBehavioural Pharmacology, 2011
- Allosteric Modulator Desformylflustrabromine Relieves the Inhibition of α2β2 and α4β2 Nicotinic Acetylcholine Receptors by β-Amyloid1–42 PeptideJournal of Molecular Neuroscience, 2011
- Nicotine-Mediated Activation of Dopaminergic Neurons in Distinct Regions of the Ventral Tegmental AreaNeuropsychopharmacology, 2011
- bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuseBritish Journal of Pharmacology, 2011
- Partial Agonists of the α3β4* Neuronal Nicotinic Acetylcholine Receptor Reduce Ethanol Consumption and Seeking in RatsNeuropsychopharmacology, 2010
- Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependenceBritish Journal of Pharmacology, 2010
- α-Conotoxin MII-Sensitive Nicotinic Acetylcholine Receptors in the Nucleus Accumbens Shell Regulate Progressive Ratio Responding Maintained by NicotineNeuropsychopharmacology, 2009
- In Vivo Activation of Midbrain Dopamine Neurons via Sensitized, High-Affinity α6∗ Nicotinic Acetylcholine ReceptorsNeuron, 2008
- Synthesis of desformylflustrabromine and its evaluation as an α4β2 and α7 nACh receptor modulatorBioorganic & Medicinal Chemistry Letters, 2007